If you require further searching capabilities for announcements please email: data@nzx.com
NZX and Media Release 31 January 2018 TruScreen January Newsletter TruScreen Limited has provided a copy of its January 2018 Newsletter. This Newsletter is also available for viewing on the company website http://truscreen.com/investor-centre/reports-presentations/. -ENDS- For more information visit www.truscreen.com or contact: Martin Dillon TruScreen Chief Executive Officer Email: martindillon@truscreen.com Media Liaison Jackie Ellis Email: jackie@ellisandco.co.nz Phone: +64 27 246 2505 About TruScreen: TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection. End CA:00313589 For:TRU Type:GENERAL Time:2018-01-31 10:30:03